3-azabicyclo[3.1.0]hexan-3-yl(4-((3-fluorophenyl)amino)-8-methylnaphthalen-1-yl)methanone | 1384250-57-0

• 分子结构分类: 有机化合物
• 英文名称: 3-azabicyclo[3.1.0]hexan-3-yl(4-((3-fluorophenyl)amino)-8-methylnaphthalen-1-yl)methanone
• 英文别名: 3-Azabicyclo[3.1.0]hexan-3-yl-[4-(3-fluoroanilino)-8-methylnaphthalen-1-yl]methanone
• CAS: 1384250-57-0
• 化学式: C₂₃H₂₁FN₂O
• 分子量: 360.431
• InChiKey: AKPSIGVTOQVDJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CANNABINOID RECEPTOR MODULATORS
  申请人：KULKARNI Sanjeev Anant

  公开号：US20130178457A1

  公开（公告）日：2013-07-11

  Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

  公式（I）的化合物以及用于制备这些化合物的方法，可用于治疗、管理和/或减轻与大麻素（CB）受体调节相关的疾病、紊乱、综合症或症状。治疗、管理和/或减轻与公式（I）的大麻素（CB）受体调节相关的疾病、紊乱、综合症或症状的方法。
• US9006442B2
  申请人：——

  公开号：US9006442B2

  公开（公告）日：2015-04-14
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS CANNABINOÏDES
  申请人：LUPIN LTD

  公开号：WO2012090177A2

  公开（公告）日：2012-07-05

  Compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE CANNABINOÏDES
  申请人：LUPIN LTD

  公开号：WO2013005168A2

  公开（公告）日：2013-01-10

  Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).